金沙检测线路js95(中国)股份有限公司-Official website

You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
创新速递
公司新闻 创新速递 媒体报道
Sutra Hemi-valve经导管二尖瓣修复系统首次应用于人体临床试验首例植入
2025-09-12 09:36:04

金沙检测线路js95-B(09996.HK)公告,最近,Sutra Medical,Inc.(集团持有战略投资的公司)成功完成其Sutra Hemi-valve经导管二尖瓣修复系统第一次应用于人体("FIM")的临床试验首例植入。该手术于新西兰怀卡托医院对一名患有严重功能性二尖瓣反流的83岁高风险患者进行,传统治疗方案不适用于该情况。患者恢复良好,于第三天出院。

公司与美国医疗器械公司Sutra订立股份购买协议,该公司设计并开发治疗心脏瓣膜病的经导管解决方案。截至本公告日期,公司为Sutra的第二大股东,仅次于Sutra创始团队。Sutra的核心在研产品Sutra Hemi-valve是一种新型后叶置换装置,通过与原生前叶无缝对合以恢复二尖瓣功能,在不阻塞左心室流出道的情况下消除二尖瓣反流。



Top
XML 地图